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Abstract
Cicatricial alopecia represents a group of disorders sharing a final pathway of destruction 
followed by replacement with fibrous tissue of the hair follicle unit. Cicatricial alopecia is 
classified into two categories, namely primary cicatricial alopecia, in which the hair follicle 
is the sole target of a progressive inflammatory process in a group of diverse skin or sys-
temic diseases, and secondary cicatricial alopecia, referring to the hair follicle destruction 
as a result of a nonspecific disruption of the dermis. Permanent hair loss may also occur in 
the late phases of some nonscarring alopecias that are called “biphasic alopecias.” Based 
on the pathological characteristics, the lesions of primary cicatricial alopecia are divided 
into lymphocyte-predominant subgroup, neutrophil-predominant subgroup, or mixed 
subgroup. In principle, the primary goal of the treatment aims to attenuate the progres-
sion of the inflammatory and the scarring processes at the earliest phase of the disease. In 
clinical practice, the lymphocyte-predominant lesions are treated with immunosuppres-
sive agents, whereas the neutrophil-predominant lesions are treated with antimicrobials 
or dapsone. As the efficacy of medication treatment against the cicatricial alopecia varies 
significantly, autologous hair transplantation is recommended to patients who have a 
relatively stable primary or a secondary cicatricial alopecia.
Keywords: cicatricial alopecia, hair follicle unit, inflammatory progression,  
hair transplantation, follicular unit extraction
1. Introduction
Alopecia, also known as baldness or hair loss, refers to the partial or complete loss of hair 
over the body, although the hair loss over the head may be the most concerned issue among 
a large number of people who pursue medical assistance. Hair loss often causes the most 
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severe psychological distress in both sexes at the onset of symptoms and negatively affects 
self-image and self-esteem of the patient. The mechanisms underlying the alopecia are not 
fully understood, but the pathological progression results in the disintegration of the follicu-
lar unit and a permanent loss of ability to produce hair fiber [1]. In contrast to androgenic hair 
loss, the most common cause of alopecia, cicatricial (scarring) alopecia represents a group of 
disorders in which the common final pathway is the destruction followed by the replacement 
with fibrous tissue of the hair follicle unit [2]. Cicatricial alopecia leads to permanent damage 
of the stem cells in the hair follicle bulge; therefore, the end result is usually a permanent or 
irreversible loss of hair leaving the effacement of follicular orifices, the replacement of follicles 
with fibrotic stelae, and the fibrosis or hyalinization of surrounding collagen in the bald skin. 
The causes of cicatricial alopecia are categorized as primary or secondary [3]. In primary 
cicatricial alopecia, the follicle unit is the sole target during the pathological progression of 
the disease. In secondary cicatricial alopecia, the hair follicle destruction occurs as a result 
of a nonspecific disruption of the dermis, as in the thermal burns or blistering disorders. 
Permanent hair loss may also occur in the late phases of some nonscarring alopecias that are 
called “biphasic alopecias.”
Pathologically, the causes of primary cicatricial alopecias are a diverse group of diseases that 
share common characteristics of skin inflammation. It is noted that the inflammatory pro-
cesses confine within the scope of the hair follicular units although the cellular or molecular 
mechanisms involved are currently ill defined. Primary cicatricial alopecias should be con-
sidered as a trichologic emergency because this disease will progress to permanent hair loss 
if the management of the inflammatory processes is delayed [4]. Nevertheless, the treatment 
options are poorly defined and often limited in effect [2]. The secondary cicatricial alopecias 
can be caused by various cutaneous inflammatory processes or by physical trauma, which 
damages the skin and skin appendages.
Cicatricial forms of alopecia account for about 3.2% [5] of all trichologic consultations and the 
frequency of cicatricial alopecia is about 5.0–7.3% of all the hair loss cases [2]. The majority 
of affected European adults were females (female:male ratio = 2.6:1), and the primary cica-
tricial alopecia is more common than the secondary (primary:secondary cicatricial alopecia 
ratio = 4:1) [5]. A survey also reported that the prevalence of primary cicatricial alopecias is 
higher in women than in men in regions of Middle East, and the possible associating fac-
tors include social culture, scarf wearing, and treatment delay. Among the diseases that may 
cause primary cicatricial alopecia, pseudopelade of Brocq (PPB) (40.6%) was the most frequent 
one followed by lichen planopilaris (LPP) (12.6%), and folliculitis decalvans (FD) (11.2%). In 
another report, however, discoid lupus erythematosus (DLE) (33.9%) was the most common 
cause followed by pseudopelade of Brocq (PPB) (24.1%) and lichen planopilaris (LPP) (22.3%) 
[6, 7]. Histopathologically, the majority cases of primary cicatricial alopecia are characterized 
by lymphocytic infiltrate.
The efficacy of the treatments for various forms of cicatricial alopecia depends on the clinical 
diagnosis that requires quality inspection of individuals during the physical exam and labora-
tory tests. The following items are routinely utilized by many clinics:
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Physical exam
A. Gross inspection of hair: (a) generalized, patterned, or focal hair loss and (b) density of 
hair, presence of broken hairs, vellus (thin, downy premature hair) vs. terminal hairs 
(thick, strong mature hair).
B. Inspection of scalp: (a) absence of follicular ostia and scar tissue and (b) papules, pustules, 
scaling, and perifollicular erythema.
C. Diagnostic procedures: (a) hair pull test: useful for telogen effluvium; performed by grasp-
ing a small portion of hair and gently applying traction while sliding the fingers along the 
hair shafts. Evaluation of results: normal: 1–2 hairs removed; abnormal: ≥6 hairs removed; 
(b) direct microscopic inspections of hair shaft: exclamation point hairs: distal end broader 
than proximal end; seen in alopecia areata. Evaluation of the results: anagen hairs: elon-
gated, distorted bulb with attached outer root sheath; telogen hair: club-shaped bulb; (c) 
“Hair growth window”: repeatedly (weekly) shaving a small area of involved scalp to 
demonstrate normal regrowth; and (d) scalp biopsy: useful for the diagnosis of scarring 
alopecias [8].
Laboratory tests
Total and free testosterone and dehydroepiandrosterone sulfate serum concentrations. This 
test is useful for diagnosis and differential diagnosis of androgenetic alopecia.
Evaluation on tissue biopsy
Two skin biopsies each with more than 4 mm in diameter are required. The biopsy punch 
should be aligned with the hair shaft angle and should reach the deep subcutis when perform-
ing tissue punch. Under a microscope, the density and ratio of each type of the infiltrating 
inflammatory cells need to be recorded. In addition, some special staining of tissue sections 
is required that usually including staining of elastic tissue, Gram stain, periodic acid-Schiff 
stain, and colloidal iron stain for mucin. Tissue cultures or immunofluorescence studies are 
often required as well [9].
Principle of treatment
Spontaneous regrowth of hair in case of cicatricial alopecia hardly ever occurs. The primary 
goal of the treatment aims to attenuation of the progression of the inflammatory and the scar-
ring processes at the earliest phase of the disease. The monitoring of disease activity by fre-
quent clinical evaluation in combination with dermatoscopy observation should be scheduled. 
A practical way to assess the treatment responses is the evaluation through dermatoscopy. 
Bear in mind however, there is so far no clear consensus regarding the successful treatments 
in terms of their efficacy to cure cicatricial alopecia, and the clinical improvement on many 
subtypes of the disease has not been fully supported by evidence-based trials. Therefore, 
the treatment of cicatricial alopecias is selected in the absence of precise information on the 
expected outcome and the current treatment failure is common.
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As a general rule, lymphocyte-predominant subgroup of primary cicatricial alopecias is 
treated with immunosuppressive agents. Neutrophil-predominant subgroup of primer cica-
tricial alopecias is treated with antimicrobials or dapsone. Systemic therapy is usually com-
bined with topical or intralesional corticosteroids or topical calcineurin inhibitors. Adding 
anti-inflammatory shampoos is often recommended. The treatment effects may take 6 months 
or more to appreciate, and disease may resume upon discontinuation of systemic and/or topi-
cal therapy. The effectiveness of maintenance therapy is still elusive [2, 10].
Surgical treatment of stable cicatricial alopecia includes hair transplantations, excision of 
affected area, flap surgery, or scar reduction with tissue expansion.
2. Pathology of cicatricial alopecia
Although cicatricial alopecia includes a group of diverse diseases, there are currently several 
pathological features that are shared among some of the different subtypes of hair loss of 
this category. Understanding of such pathology traits would help understand the treatment 
strategies. From the clinical points of view, the pathological pathways of primary cicatricial 
alopecias merge into a few inflammatory processes that eventually result in the disintegration 
of hair follicular units. By consensus, four main categories are proposed based on the types 
of immune cell infiltrates during the pathogenesis of primary cicatricial alopecia (Table 1) [4].
Lymphocytic cicatricial alopecia
Chronic cutaneous lupus erythematosus
Lichen planopilaris (LPP)
Classic LPP
Frontal fibrosing alopecia
Graham-Little syndrome
Classic pseudopelade (Brocq)
Central centrifugal cicatricial alopecia
Alopecia mucinosa
Keratosis follicularis spinulosa decalvans
Neutrophilic cicatricial alopecia
Folliculitis decalvans
Dissecting cellulitis/folliculitis (perifolliculitis abscedens et suffodiens)
Keratosis follicularis spinulosa decalvans (KFSD)
Mixed cicatricial alopecia
Folliculitis (acne) keloidalis
Folliculitis (acne) necrotica
Erosive pustular dermatosis
Nonspecific cicatricial alopecia
Sebaceous gland abnormalities (primary or secondary)
Table 1. Immune cell infiltrates and their corresponding clinical diseases.
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Several lines of evidences in basic and clinical research have indicated that the local inflam-
matory destruction of the pilosebaceous unit leads to the permanent damage of the follicular 
stem cells in the bulge region and several associated hypotheses are suggested as following 
[1]: Autoimmune-mediated hypothesis: The autoantigens/epitopes that could elicit the auto-
immune response are formed in the permanent region of the follicle including the stem cells 
in the bulge area; (2) immune privilege breakdown and Langerhans cell distribution hypoth-
esis: MHC class I, β2-microglobulin, and MHC class II immune reactivity are significantly up-
regulated in the bulge region, and this reaction may be triggered by aberrant distribution of 
Langerhans cells; (3) bulge stem cell destruction hypothesis: The lost of Ck15 positive bulge 
stem cells is one of the evident histopathological traits of primary cicatricial alopecia; (4) hair 
Follicle Epithelial-Mesenchymal Communication Inhibition Hypothesis: As the induction of 
life-long cyclic transformations of hair follicles is epithelial-mesenchymal interaction depen-
dent, inflammatory interruption in the communication between the epithelial stem cells and the 
hair follicle mesenchyme would damage the integrity of hair follicles [2]. (5) Peroxisome prolif-
erator-activated receptor-γ (PPAR-γ) deletion hypothesis [2]: PPAR-𝛾, which is highly expressed 
in human sebaceous glands, plays roles in lipid homeostasis, sebocyte maturation, peroxisome 
biogenesis and anti-inflammatory effects. Dysfunction of PPAR-𝛾 is believed to result in fol-
licular inflammation and the pathogenesis of the primary cicatricial alopecia [11]; (6) Sebaceous 
Gland Dysfunction Hypothesis: The aberrant gene expressions in sebaceous gland lead to the 
abnormalities in the sebum secretion and hair growth; (7) “No Danger” Signal CD200 Deletion 
Hypothesis: In this hypothesis, the interruption of the ligand-binding signal between CD200 
and its receptor is speculated as the trigger of local inflammatory reactions [12]; (8) Genetic 
Mutation of Keratin Hypothesis [2]: keratin gene mutation that associated with pathogenesis of 
alopecia microacanthosis leads to the disintegration of hair follicles.
As for secondary cicatricial alopecia, Table 2 lists the lesions commonly seen in clinics that 
eventually result in reversible or irreversible hair loss.
Infection
Fungal (tinea capitis)
Bacterial
Viral (e.g., herpes zoster)
Immunologic
Sarcoidosis
Necrobiosis lipoidica
Morphea
Graft-versus-host disease
Malignancies
Alopecia neoplastica
Lymphoproliferative
Exogenous factors
Radiation
Burns
Drugs
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Another form of alopecia that is characterized by “biphasic pattern” also involves the scar-
ring processes pathologically. Clinical observations suggest that this form of alopecia may be 
irreversible. Examples of the clinical diseases that can be categorized in this form are known 
as “Late-stage nonscarring alopecias” including alopecia areata, patterned hair loss, and trac-
tion alopecia, etc. Recent report indicated that the occurrence of biphasic alopecia can also be 
iatrogenic [13].
3. Clinical features of cicatricial alopecia
According to the clinical course, physicians tend to classify all forms of cicatricial alopecias 
into unstable group, meaning there is an increased recurrence even with the treatment, and 
stable group, referring to the forms of cicatricial alopecia that have a low recurrent rate after 
treatment. The formal form usually includes lichen planopilaris, pseudopelade of Brocq, and 
discoid lupus erythematosus, whereas the latter form includes isolated traumas, burns, infec-
tion, and prior surgery-induced alopecias.
The clinical treatment options for cicatricial alopecia are summarized in Figure 1.
3.1. Characteristics of primary cicatricial alopecia
Several factors may have associated with the distribution of primary cicatricial alopecia 
throughout the world. For example, lymphocytic form dominants among North and South 
American and Iranian patient groups, whereas neutrophilic form is the dominant one among 
Chinese patient group [14, 15]. The occurrences of dissecting cellulitis and acne keloidalis 
nuchae may have close association with genetic background and are seen more frequently in 
patients of African descent. Sex is another factor believed to be related with the prevalence 
of primary cicatricial alopecia. Folliculitis decalvans, dissecting cellulitis, and acne keloidalis 
nuchae are more common in males, while central centrifugal cicatricial alopecia, lichen plano-
pilaris, discoid lupus erythematosus, and pseudopelade of Brocq have a female predominance. 
In addition, discoid lupus erythematosus, dissecting cellulitis, and acne keloidalis nuchae are 
frequently seen in younger patients, whereas central centrifugal cicatricial alopecia, lichen 
Dermatoses
Psoriasis
Bullous disorders
Cicatricial pemphigoid
Epidermolysis bullosa
Hamartomas
Organoid nevus
Miscellaneous
Lipedematous alopecia
Table 2. Etiology of secondary cicatricial alopecia.
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planopilaris, and folliculitis decalvans tend to be distributed among older patients. Lastly, 
there are correlations between certain forms of cicatricial alopecia and the patterns of the 
baldness. For example, unifocal-ragged border of bald area may associate with central centrif-
ugal cicatricial alopecia and discoid lupus erythematosus, multifocal-interconnected pattern 
may often be seen in lichen planopilaris and folliculitis decalvans, and multifocal-separated 
pattern may be one of the characteristics of clinical feature of dissecting cellulitis.
3.2. Lymphocytic cicatricial alopecia
3.2.1. Chronic cutaneous lupus erythematosus (classic discoid lupus erythematosus)
3.2.1.1. Clinical features
This is one of the major forms of cicatricial alopecia among European patients and typically 
affects women with age between 20 and 60 years old [9, 16]. It presents with erythematous 
scaly papules with characteristic follicular plugging (Figure 2). The lesions evolve into hypo- 
or depigmented atrophic plaques with peripheral hyperpigmentation, overlying telangiecta-
sias, and loss of follicles. Systemic lupus erythematosus (SLE) associates with 20% of cases [17], 
and the detections of antinuclear antibodies are positive in approximately 20% of cases [16].
Figure 1. Schematic diagram of treatment options.
Cicatricial Alopecia
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3.2.1.2. Pathological features
Interface dermatitis with epidermal atrophy or hyperplasia in the hypertrophic variant of 
chronic cutaneous lupus erythematosus; ortho-hyperkeratosis with areas of parakeratosis 
and follicular plugging; an inflammatory lymphocytes infiltrate with admixed plasma cells 
distributed around the superficial and deeper dermal vasculature as well as adnexal structures 
and scattered within the interstitium; early destruction of sebaceous glands; replacement of 
the follicle with fibrous tissue in late stages; hair fiber granulomas on occasion; occasional 
inflammatory infiltrate into the subcutis with lymphoid follicle formation [18].
3.2.1.3. Featured stainings
Periodic acid-Schiff (PAS) stains showing thickened PAS-positive basement membrane zone; 
mucin deposition in reticular dermis or perifollicular scarring tissues; immunofluorescence 
staining positive signals of IgG, IgM, and complement C3 along the dermal-epidermal or 
follicular epithelial-dermal junction [19, 20].
3.2.1.4. Treatment
First-line systemic therapy: hydroxychloroquine (HCQ).
3.2.2. Lichen planopilaris (LPP)
3.2.2.1. Clinical features
The lesion appears at the scalp in about half of the cases. Some of the lesions may develop to 
mucous membranes [2]. Clinically, hair loss can be patchy or diffuse and presents with peri-
follicular erythematous papules and acuminate hyperkeratotic follicular spines (Figure 3). 
The disease is most active at the hairbearing periphery of the alopecic patch [21].
Lichen planopilaris and frontal fibrosing alopecia are slowly progressive with episodes of 
worsening. Systemic therapy is strongly recommended if symptoms or hair loss is persistent 
or progressive.
Figure 2. Alopecia at occiput region in a patient with cutaneous lupus erythematosus.
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3.2.2.2. Pathological features
Lichenoid band-like infiltrate in the infundibulum, isthmus, and variably the interfollicular 
epidermis regions; cytoid bodies, basal vacuolization, pigment incontinence, and Max Joseph 
spaces along the follicular epithelium; follicular plugging; concentric lamellar fibroplasia, loss 
of sebaceous glands and follicles [22, 23].
Vague mucin deposition in dermis; loss of elastic tissue staining of the upper third of the 
fibrous tract, and associated destruction of the elastic sheath in late-stage lesions.
Nonspecific IgM within cytoid bodies along the upper hair follicle on direct immunofluores-
cence observation [24].
3.2.2.3. Treatment
First-line therapy: systemic medications, tetracycline antibiotics, or HCQ. Tetracycline 500 mg 
twice daily and doxycycline hyclate 100 mg twice daily. The mechanism of action is thought 
to be due to the anti-inflammatory benefits of the tetracycline antibiotics. The medications are 
recommended to be limited to 6 months. The efficacy of HCQ in LPP is identical to that of 
tetracyclines [25].
3.2.3. Frontal fibrosing alopecia (FFA)
3.2.3.1. Clinical features
Frontal fibrosing alopecia, as described by Kossard, is a scarring alopecia that occurs most 
often in postmenopausal women [26]. It is clinically characterized by a progressive recession 
of the frontal and temporal hair lines with follicular hyperkeratosis, perifollicular erythema, 
and loss of follicular ostia [2]. More than half of the FFA patients also have eyebrow hair loss.
3.2.3.2. Pathological features
Histopathology shows a lichenoid reaction against miniaturized hair follicles.
Figure 3. Scalp lesion of lichen planopilaris leads to alopecic patches.
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3.2.4. Graham-Little syndrome
Patchy, progressive scarring alopecia of the scalp, nonscarring alopecia of axillary and pubic 
hair, and the presence of widespread horny follicular papules on the trunk and limbs are 
clinical traits of Graham-Little syndrome [2].
3.2.5. Classic pseudopelade (Brocq)
3.2.5.1. Clinical features
Classic pseudopelade is a rare, slowly progressive hair disorder of typically the most common 
form observed in middle-aged Caucasian women. It is presented footprints in the snow to 
round hypopigmented atrophic alopecic plaques resembling “footprints in the snow” [27].
3.2.5.2. Pathological features
Perifollicular lymphocytic infiltrate, with eccentric atrophy of the outer root sheath epithe-
lium, prominent concentric lamellar fibroplasia, loss of sebaceous glands and follicles, and 
hair-shaft granulomas [15].
Elastic fibers are markedly thickened in pseudopelade of Brocq. Direct immunofluorescence 
usually negative but may reveal scant finely granular IgM along the basement membrane 
zone of the follicular infundibulum [28].
3.2.6. Central centrifugal cicatricial alopecia
3.2.6.1. Clinical features
It is commonly seen in young to middle-aged women of African-American descent with 
a prevalence of 3–6% [29–31]. It presents progressive alopecia over the crown and vertex 
that expands centrifugally without overt inflammation and with tufting and perifollicular 
hyperpigmentation.
3.2.6.2. Pathological features
Premature desquamation of the inner root sheath; perifollicular lymphocytic inflammation of 
the infundibulum and isthmus; eccentric atrophy of the outer root sheath epithelium, concen-
tric lamellar fibroplasia, and hair fiber granulomas within fibrous tract remnants [32].
Preserved elastic sheath and thickened dermal elastic fibers. Direct immunofluorescence usu-
ally negative [33].
3.2.7. Alopecia mucinosa
3.2.7.1. Clinical features
Papules and plaques of hair loss with variable dysesthesia and anhidrosis on the eyebrows, 
scalp, trunk, and limbs. Presents in all age groups. May be benign or associated with lym-
phoma (especially mycosis fungoides).
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3.2.7.2. Pathological features
Lymphocytic inflammation around perifollicle; variably atypical lymphocytes; restricted 
T-cell lineages seen in benign and malignant forms.
Direct immunofluorescence negative.
3.2.7.3. Treatment
Tetracycline antibiotics typically are helpful although not recommended for systemic therapy. 
Improvement may be seen within 2–6 months followed by dose reduction [34].
3.2.8. Keratosis follicularis spinulosa decalvans
3.2.8.1. Clinical features
An X-linked disorder of cornification with the onset of the alopecia in the teenage years. 
Acuminate keratotic follicular papules and pustules on the scalp, eyebrows, and eyelashes, 
keratosis pilaris on the trunk and extremities, photophobia, and corneal dystrophy as the 
clinical characteristics.
3.2.8.2. Pathological features
Follicular plug with compact hyperkeratosis and hypergranulosis; upper follicle lympho-
cytic infiltrate; concentric lamellar fibrosis, hair shaft granulomas, and fibrous follicular tract 
remnants.
3.2.8.3. Treatment
Etretinate, isotretinoin, oral antibiotics, and dapsone are reported medications [35].
In summary, lymphocytic primary scarring alopecias generally can be treated with tetra-
cycline antibiotics, HCQ (hydroxychloroquine), or immunosuppressant medications such 
as corticosteroids, cyclosporine, and mycophenolate mofetil. Auxiliary drugs are also used 
specifically for some types of diseases. For example, pioglitazone or 5-alpha reductase 
inhibitors are used for LPP or FFA, respectively. Treatment response can be seen typically 
between 6 and 12 months, and gradual taper may result in sustained remission after discon-
tinuation of oral therapy [7, 10].
3.3. Neutrophilic cicatricial alopecia
3.3.1. Folliculitis decalvans
3.3.1.1. Clinical features
Occurs primarily in young and middle-aged adults with a slight predominance in men. 
Multiple hairs emerge from a single follicular orifice in a pattern known as "tufted hair 
folliculitis." Erythematous follicular papules or pustules on the crown progress to pseu-
dopelade-like round alopecic patches with pustules at the advancing margins and with 
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polytrichia. Staphylococcus aureus is commonly isolated from primary lesions. Dermoscope 
examination reveals low hair density and loss of follicular ostia, thinned shafts of the 
remaining hairs [24].
3.3.1.2. Pathological features
Follicular plugging and intra/perifollicular neutrophilic infiltrate of the upper and middle 
portions of the hair follicle; follicular rupture with infiltrates of lymphocytes, histiocytes, and 
plasma cells; neutrophilic abscess is common; hair shaft granulomas prominent; late-stage 
replacement of hair follicles with scarred fibrous tracts. Existence of plasma cells has diagnos-
tic significance in advanced cases.
3.3.1.3. Treatment
First-line treatment: oral administration of tetracycline, doxycycline, minocycline, erythro-
mycin, and clindamycin alone or in combination with rifampin. However, relapse is common 
after discontinuation of these antibiotics [36].
3.3.2. Dissecting cellulitis/folliculitis (perifolliculitis abscedens et suffodiens)
3.3.2.1. Clinical features
Commonly seen in younger men of African Americans with inflammatory plaques and nodules, 
often associated with formation of sinus tracts that exude a purulent discharge. The process com-
monly begins on the occiput or vertex and often progress to involve the entire scalp (Figure 4). 
Recurrent bacterial infections and disordered keratinization are important causes [19].
Figure 4. A patient with dissecting cellulitis/folliculitis presents with inflammatory plaques, nodules, and purulent 
discharges over the entire scalp.
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3.3.2.2. Pathological features
Follicular plugging and collections of neutrophils at the follicular ostia; extensive abscess for-
mation and extensive dermal fibrosis.
3.4. Mixed cicatricial alopecia
3.4.1. Folliculitis (acne) keloidalis
3.4.1.1. Clinical features
Most frequently in African postpubertal males with follicular erythematous papules and pus-
tules that progress to hairless keloid-like nodules.
3.4.1.2. Pathological features
Neutrophilic or lymphoplasmacytic perifollicular infiltrate; thinned outer root sheath with 
reparative concentric lamellar fibroplasia; follicles are destroyed, hair-shaft fragments are 
extruded; hair-shaft granulomas or microabscess formation are prominent [2].
3.4.2. Folliculitis (acne) necrotica
3.4.2.1. Clinical features
Lesions present as crops of red-brown papules and papulopustules that undergo necrosis and 
become punched out, depressed scars after eventual healing.
3.4.2.2. Pathological features
Fragments of hair shaft; scattered neutrophils are present in the superficial dermis where 
follicular epithelium undergoes necrosis [7].
3.4.3. Erosive pustular dermatosis
3.4.3.1. Clinical features
Primarily affects elderly women and presents with extensive, boggy, crusted, erosive plaques 
on the scalp. It is thought to be triggered by local trauma sometimes months to years prior to 
the appearance of lesions or occur as a result of autoimmune disease [37].
3.4.3.2. Pathological features
Nonspecific findings in biopsy samples indicate the epidermis may be ulcerated or appear 
atrophic or hyperplastic. A mixed patchy dermal inflammatory infiltrate is seen. Suppurative 
folliculitis, intraepidermal, and subepidermal neutrophil infiltrates are common. Dermal 
fibrosis may focally replace the follicles or may diffusely involve the dermis, depending on 
the extent of inflammation. Scattered naked hairshaft granulomas are also seen in later stages.
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3.5. Characteristics of secondary cicatricial alopecia
The causes of secondary cicatricial alopecia include even more diverse forms of trauma and 
inflammatory injuries. Of note, iatrogenic cause of hair loss such as with esthetic surgery is a 
concern among both patients and physicians. Currently, there is no effective treatment proto-
col for any subtypes of secondary cicatricial alopecia except to attenuate the development of 
inflammation processes initiated by topical tissue damages or infection. Medications used for 
these purposes include high-potency topical corticosteroids, immunosuppressants, and anti-
biotics. Nevertheless, permanent hair loss may eventually be the outcome, and the baldness 
Figure 5. Reconstruction of secondary cicatricial alopecic region with expanded scalp flaps. (a–c) Photographs of a 
patient with thermal injury induced alopecia; (d, e) Photographs taken at post-operative day 7 after reconstruction of 
bald areas with expanded skin flaps; and (f, g) Follow-up photographs taken at month 29 post-operatively.
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would become evident if the area of the secondary cicatricial alopecia is extensive (Figure 5). 
Therefore, autologous hair transplantation and replacement of the bald skin with skin flaps 
that have hairs with satisfactory density are acceptable procedures for this form of alopecia [2].
3.6. Biphasic alopecias
The term “biphasic alopecia" includes some conditions where cicatricial alopecia becomes appar-
ent in the late stages of an otherwise nonscarring form of alopecia. Alopecia areata, androgenetic 
alopecia, and traction alopecia may belong to this category. Alopecia areata can result in fibrosis 
in 10% of cases, while in advanced stages of androgenetic alopecia, vellus hairs also disappear 
and the alopecia becomes permanent [2]. We have noticed that esthetic filling with hyaluronic 
acid (HA) can induce biphasic alopecia that may leave permanent hair loss in the severely 
necrotic lesion region, whereas hair regrowth was found in possible less ischemic area (Figure 6).
3.7. The application of minoxidil
Minoxidil has demonstrated an antifibrotic action and believed to be efficient in the early course 
of some dermatoses leading to scarring alopecia, such as scalp burning disease. Mechanistically, 
Figure 6. Hyaluronic acid filling in the left temple region results in the skin necrotic and ischemic lesion leading to an 
area of a permanent hair loss surrounded by regions with slow-restoration of hair regrowth [13]. (a) Complete hair loss 
was seen in the patient’s left temple area after HA injection. A HA injection induced necrotic skin crust surrounded by 
bald skin area at day 22 is shown; (b) near healed prior necrotic skin and surrounding skin still showed no sign of hair 
regrowth at post-HA injection day 42 post-HA injection; (c) partial hair regrowth was seen in the bald area except the 
prior necrotic crust covered region at post-HA injection day 74; and (d) a view of long-term recover of hair regrowth 
surrounding a permanent bald area at post-HA injection day 209.
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scalp sulfotransferase changes minoxidil into minoxidil sulfate, which is thought to be the active 
form of the molecule. The variations of sulfotransferase activity between individuals may explain 
the interindividual variations in minoxidil efficiency. Minoxidil acts by shortening telogen phase 
and thus causing the quiescent hair follicles to enter prematurely into anagen phase, resulting in 
telogen effluvium after the initiation of minoxidil therapy, although such effect of minoxidil may 
increase hair length and diameter. Some basic research results suggest that minoxidil can intervene 
on the potassium channels of the vascular smooth muscles and hair follicles, which may induce 
the following effects: (1) stimulation of the microcirculation near the hair follicles by inducing arte-
riolar vasodilation, which may cause hair growth. Minoxidil induces the expression of vascular 
endothelial growth factor (VEGF) which increases vascularization around the hair follicles, thus 
contributing to hair growth; (2) activation of the prostaglandin-endoperoxide synthase one which 
stimulates hair growth; (3) inhibition of the effects of androgens on the androgen-sensitive hair 
follicles; and (4) direct stimulating action on the hair follicles: Minoxidil may act as an ‘epidermal 
growth factor’ on matrix cells delaying their aging, thus prolonging the duration of anagen phase, 
probably via the activation of the beta-catenin pathway [38–40].The effect of minoxidil becomes 
evident after approximately 8 weeks post-treatment, and the maximal effect may be seen after 
4 months. Most of the clinical responders to minoxidil have alopecia with the onset of less than 
5 years, particularly among young adults, with their follicles not deeply miniaturized [41].
Minoxidil is well tolerated. However, propylene glycol contained in the liquid form (solution) 
of minoxidil may be the cause of some adverse effects reported by patients that include: (1) 
minoxidil-induced telogen effluvium: the shortening of telogen phase by minoxidil causes 
marked shedding; (2) skin irritation: with erythema, discomfort, and burn sensation; (3) scaly 
changes of the scalp: due to irritation or exacerbation of seborrheic dermatitis; (4) isolated 
itching; (5) allergic contact dermatitis: with erythema, eczematous skin reaction, and itching. 
Minoxidil and propylene glycol are the major allergens in allergic contact dermatitis. Patch 
testing may be helpful to reveal the causative agent. In case of allergic contact dermatitis 
to propylene glycol, minoxidil foam (i.e., not containing propylene glycol) may be used; (6) 
localized or generalized hypertrichosis: this effect seen during oral minoxidil treatment may 
also be observed with topical form. It is probably related to the prolongation of anagen phase. 
This effect seems to be more commonly encountered with 5% minoxidil than 2% minoxidil.
Percutaneous toxicity is exceptional after a conventional use of minoxidil which has no 
known antidote for minoxidil massive oral ingestion. Accidental oral ingestion of minoxidil 
results in mild vomiting and rarely requires hospitalization. However, cases of hypoten-
sion, tachycardia, and/or electrocardiographic changes after accidental ingestion have been 
reported. Refractory hypotension may be managed by intravenous fluids and vasopressor 
agents. Gastric wash and activated charcoal may be indicated to prevent systemic toxicity in 
massive accidental ingestion of minoxidil.
3.8. Hair transplantation
The hair transplantation replaces the lost hairs with autologous hairs harvested from donor 
sites. Based on clinical experience, another 2 years may be required before the recipient site 
fully supports the survival and growth of hair grafts after the disease is stabilised. For limited 
area of hair loss, select local skin flap. For large bald area, expanded scalp skin flap can be 
selected or select hair transplantation technique [42, 43] (Figure 5).
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For transplantation procedure, here we briefly introduce follicular unit extraction (FUE) tech-
nique. It is the treatment of choice in instances where there is good availability of donor hair 
and vascular circulation [44]. Briefly, in FUE surgery, there is no linear scar but instead each 
extraction site leaves a small round dot scar that can be hidden even with shorter hairstyles 
compared to a strip scar (Figure 8). The punches vary in size but generally are in the range of 
0.75–1.2 mm in diameter attached to either a hand-held manual device, a hand-held mecha-
nized drill device or an automated robotic device. The recommended density of the site in 
the recipient area is 15–20 FU/cm2 in areas with low perfusion and 20–30 FU/cm2 in areas 
with sufficient blood perfusion. The integrated grafts started to grow 4–5 months after the 
surgery and most entered the anagen phase approximately 1 year postoperatively (Figure 7). 
For hair loss from burn injury, successful treatment with hair transplantation was reported 
although the hair follicle graft survival rate in scar tissue can be varied significantly [43–45].
Advantages of FUE include the absence of suture wounds and linear scars, less bleeding, and 
less postoperative discomfort than follicular unit transplantation. In addition, it is suitable 
for patients with less scalp laxity and poor wound healing. Furthermore, scarring at each 
individual site may limit the possibility of harvesting hair in the same area in the future. 
Moreover, the hair transection rate is higher than in follicular unit transplantation and buried 
tissue can cause inflammation and cyst formation [44].
Figure 7. Autologous hair transplantation. (a) Burns induced hair loss in the temple region; (b) seven days after hair 
transplantation by FUE technique; and (c, d) photographs of hair regrowth at month 11 after hair transplantation.
Figure 8. Linear scar at the donor site resulted from FUT procedure. (a) A linear scar with loss of hair is visible at the 
occiput donor region after FUT procedure and (b) the scar is invisible after hair implantation by a FUE procedure.
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Disadvantages of this technique are that large harvesting sessions require the entire donor 
area to be shaved and the grafts tend to have less tissue around them and therefore more 
care is needed in handling them. Only with multiple or ill-planned procedures, there will be 
thinning out of the donor area.
Currently, the recipient holes or slits are made using either a punch, scalpel, different types of 
needles, or automated devices. A novel technique based on CO
2
 laser tissue ablation was intro-
duced in 1994 by Unger and David. However, one major possible disadvantage is the known 
thermal coagulation zone more or less present in all CO
2
-based laser systems. Such thermal 
damage may raise concerns of reduced blood perfusion present in treated scar tissue [46].
The Er:YAG laser produces energy in the mid-infrared light spectrum at 2940 nm. This 
wavelength has 10–15 times greater water absorption than a CO
2
 laser with an emission at 
10,600 nm. Together with a pulse below the thermal relaxation time of skin, the Er:YAG laser 
allows “cold”-ablation with very little vaporization and desiccation. Minimal damage of the 
surrounding tissue combined with the precision of a laser should make this a valuable instru-
ment for creating holes or slits for hair transplantation in cicatricial alopecia [46].
4. Conclusions
Cicatricial alopecia refers to a diverse group of local and systemic diseases in which hair loss 
is one of the outcomes. Although efforts have been made through medication treatments to 
counter the pathologic progression that would damage and replace the follicular unit with 
fibrous scarring, the efficacy of each treatment protocol may still lack of the supports through 
evidence-based studies, therefore, warranting further basic and clinical investigation. In 
contrast, hair transplantation has demonstrated more predictable and satisfactory outcome. 
Nevertheless, preparation of scalp recipient tissue with medication prior the surgery and 
post-surgery care with professional assistance are imperative for the survival and long-term 
maintenance of hair grafts.
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Acronyms and abbreviations
Brocq classic pseudopelade
CCCA central centrifugal cicatricial alopecia
CK cytokeratin
CO
2
 carbon dioxide
FD folliculitis decalvans
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FFA frontal fibrosing alopecia
FUE follicular unit extraction
HA hyaluronic acid
HCQ hydroxychloroquine
KFSD keratosis follicularis spinulosa decalvans
LPP lichen planopilaris
MHC major histocompatibility complex
PCAs primary cicatricial alopecias
PPAR-γ peroxisome proliferator-activated receptor-γ
PPB pseudopelade of Brocq
PAS periodic acid-Schiff
SLE systemic lupus erythematosus
VEGF vascular endothelial growth factor
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